Droxidopa is a prodrug of norepinephrine used to increase the concentrations of these neurotransmitters in the body and brain. It is metabolized by aromatic L-amino acid decarboxylase (AAAD), also known as DOPA decarboxylase (DDC). Patients with NOH have depleted levels of norepinephrine which leads to decreased blood pressure or hypotension upon orthostatic challenge.[6] Droxidopa works by increasing the levels of norepinephrine in the peripheral nervous system (PNS), thus enabling the body to maintain blood flow upon and while standing. Droxidopa can also cross the blood–brain barrier (BBB) where it is converted to norepinephrine from within the brain. Increased levels of norepinephrine in the central nervous system (CNS) may be beneficial to patients in a wide range of indications. Droxidopa can be coupled with a peripheral aromatic L-amino acid decarboxylase inhibitor (AAADI) or DOPA decarboxylase inhibitor (DDC) such as carbidopa (Lodosyn) to increase central norepinephrine concentrations while minimizing increases of peripheral levels.
The global market for Droxidopa was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Droxidopa was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Droxidopa was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Droxidopa was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Droxidopa include Piramal Enterprises Limited, Lupin Ltd, Sun Pharmaceutical Industries Ltd., Clarochem Ireland, Estechpharma Co., Ltd., Chongqing Shenghuaxi Pharm Co.,Ltd. and JINLAN Pharm-Drugs Technology Co., Ltd., etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Droxidopa, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Droxidopa by region & country, by Type, and by Application.
The Droxidopa market size, estimations, and forecasts are provided in terms of sales volume (Ton) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Droxidopa.
Market Segmentation
By Company
Piramal Enterprises Limited
Lupin Ltd
Sun Pharmaceutical Industries Ltd.
Clarochem Ireland
Estechpharma Co., Ltd.
Chongqing Shenghuaxi Pharm Co.,Ltd.
JINLAN Pharm-Drugs Technology Co., Ltd.
Segment by Type:
±Ê³Ü°ù¾±³Ù²â≥98%
Purity<98%
Segment by Application
Droxidopa Tablets
Droxidopa Capsules
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Droxidopa manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Droxidopa in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Droxidopa in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Droxidopa Product Introduction
1.2 Global Droxidopa Market Size Forecast
1.2.1 Global Droxidopa Sales Value (2019-2030)
1.2.2 Global Droxidopa Sales Volume (2019-2030)
1.2.3 Global Droxidopa Sales Price (2019-2030)
1.3 Droxidopa Market Trends & Drivers
1.3.1 Droxidopa Industry Trends
1.3.2 Droxidopa Market Drivers & Opportunity
1.3.3 Droxidopa Market Challenges
1.3.4 Droxidopa Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Droxidopa Players Revenue Ranking (2023)
2.2 Global Droxidopa Revenue by Company (2019-2024)
2.3 Global Droxidopa Players Sales Volume Ranking (2023)
2.4 Global Droxidopa Sales Volume by Company Players (2019-2024)
2.5 Global Droxidopa Average Price by Company (2019-2024)
2.6 Key Manufacturers Droxidopa Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Droxidopa Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Droxidopa
2.9 Droxidopa Market Competitive Analysis
2.9.1 Droxidopa Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Droxidopa Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Droxidopa as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 ±Ê³Ü°ù¾±³Ù²â≥98%
3.1.2 Purity<98%
3.2 Global Droxidopa Sales Value by Type
3.2.1 Global Droxidopa Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Droxidopa Sales Value, by Type (2019-2030)
3.2.3 Global Droxidopa Sales Value, by Type (%) (2019-2030)
3.3 Global Droxidopa Sales Volume by Type
3.3.1 Global Droxidopa Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Droxidopa Sales Volume, by Type (2019-2030)
3.3.3 Global Droxidopa Sales Volume, by Type (%) (2019-2030)
3.4 Global Droxidopa Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Droxidopa Tablets
4.1.2 Droxidopa Capsules
4.1.3 Others
4.2 Global Droxidopa Sales Value by Application
4.2.1 Global Droxidopa Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Droxidopa Sales Value, by Application (2019-2030)
4.2.3 Global Droxidopa Sales Value, by Application (%) (2019-2030)
4.3 Global Droxidopa Sales Volume by Application
4.3.1 Global Droxidopa Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Droxidopa Sales Volume, by Application (2019-2030)
4.3.3 Global Droxidopa Sales Volume, by Application (%) (2019-2030)
4.4 Global Droxidopa Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Droxidopa Sales Value by Region
5.1.1 Global Droxidopa Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Droxidopa Sales Value by Region (2019-2024)
5.1.3 Global Droxidopa Sales Value by Region (2025-2030)
5.1.4 Global Droxidopa Sales Value by Region (%), (2019-2030)
5.2 Global Droxidopa Sales Volume by Region
5.2.1 Global Droxidopa Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Droxidopa Sales Volume by Region (2019-2024)
5.2.3 Global Droxidopa Sales Volume by Region (2025-2030)
5.2.4 Global Droxidopa Sales Volume by Region (%), (2019-2030)
5.3 Global Droxidopa Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Droxidopa Sales Value, 2019-2030
5.4.2 North America Droxidopa Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Droxidopa Sales Value, 2019-2030
5.5.2 Europe Droxidopa Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Droxidopa Sales Value, 2019-2030
5.6.2 Asia Pacific Droxidopa Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Droxidopa Sales Value, 2019-2030
5.7.2 South America Droxidopa Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Droxidopa Sales Value, 2019-2030
5.8.2 Middle East & Africa Droxidopa Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Droxidopa Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Droxidopa Sales Value
6.2.1 Key Countries/Regions Droxidopa Sales Value, 2019-2030
6.2.2 Key Countries/Regions Droxidopa Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Droxidopa Sales Value, 2019-2030
6.3.2 United States Droxidopa Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Droxidopa Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Droxidopa Sales Value, 2019-2030
6.4.2 Europe Droxidopa Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Droxidopa Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Droxidopa Sales Value, 2019-2030
6.5.2 China Droxidopa Sales Value by Type (%), 2023 VS 2030
6.5.3 China Droxidopa Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Droxidopa Sales Value, 2019-2030
6.6.2 Japan Droxidopa Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Droxidopa Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Droxidopa Sales Value, 2019-2030
6.7.2 South Korea Droxidopa Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Droxidopa Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Droxidopa Sales Value, 2019-2030
6.8.2 Southeast Asia Droxidopa Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Droxidopa Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Droxidopa Sales Value, 2019-2030
6.9.2 India Droxidopa Sales Value by Type (%), 2023 VS 2030
6.9.3 India Droxidopa Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Piramal Enterprises Limited
7.1.1 Piramal Enterprises Limited Company Information
7.1.2 Piramal Enterprises Limited Introduction and Business Overview
7.1.3 Piramal Enterprises Limited Droxidopa Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Piramal Enterprises Limited Droxidopa Product Offerings
7.1.5 Piramal Enterprises Limited Recent Development
7.2 Lupin Ltd
7.2.1 Lupin Ltd Company Information
7.2.2 Lupin Ltd Introduction and Business Overview
7.2.3 Lupin Ltd Droxidopa Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Lupin Ltd Droxidopa Product Offerings
7.2.5 Lupin Ltd Recent Development
7.3 Sun Pharmaceutical Industries Ltd.
7.3.1 Sun Pharmaceutical Industries Ltd. Company Information
7.3.2 Sun Pharmaceutical Industries Ltd. Introduction and Business Overview
7.3.3 Sun Pharmaceutical Industries Ltd. Droxidopa Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Sun Pharmaceutical Industries Ltd. Droxidopa Product Offerings
7.3.5 Sun Pharmaceutical Industries Ltd. Recent Development
7.4 Clarochem Ireland
7.4.1 Clarochem Ireland Company Information
7.4.2 Clarochem Ireland Introduction and Business Overview
7.4.3 Clarochem Ireland Droxidopa Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Clarochem Ireland Droxidopa Product Offerings
7.4.5 Clarochem Ireland Recent Development
7.5 Estechpharma Co., Ltd.
7.5.1 Estechpharma Co., Ltd. Company Information
7.5.2 Estechpharma Co., Ltd. Introduction and Business Overview
7.5.3 Estechpharma Co., Ltd. Droxidopa Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Estechpharma Co., Ltd. Droxidopa Product Offerings
7.5.5 Estechpharma Co., Ltd. Recent Development
7.6 Chongqing Shenghuaxi Pharm Co.,Ltd.
7.6.1 Chongqing Shenghuaxi Pharm Co.,Ltd. Company Information
7.6.2 Chongqing Shenghuaxi Pharm Co.,Ltd. Introduction and Business Overview
7.6.3 Chongqing Shenghuaxi Pharm Co.,Ltd. Droxidopa Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Chongqing Shenghuaxi Pharm Co.,Ltd. Droxidopa Product Offerings
7.6.5 Chongqing Shenghuaxi Pharm Co.,Ltd. Recent Development
7.7 JINLAN Pharm-Drugs Technology Co., Ltd.
7.7.1 JINLAN Pharm-Drugs Technology Co., Ltd. Company Information
7.7.2 JINLAN Pharm-Drugs Technology Co., Ltd. Introduction and Business Overview
7.7.3 JINLAN Pharm-Drugs Technology Co., Ltd. Droxidopa Sales, Revenue and Gross Margin (2019-2024)
7.7.4 JINLAN Pharm-Drugs Technology Co., Ltd. Droxidopa Product Offerings
7.7.5 JINLAN Pharm-Drugs Technology Co., Ltd. Recent Development
8 Industry Chain Analysis
8.1 Droxidopa Industrial Chain
8.2 Droxidopa Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Droxidopa Sales Model
8.5.2 Sales Channel
8.5.3 Droxidopa Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Piramal Enterprises Limited
Lupin Ltd
Sun Pharmaceutical Industries Ltd.
Clarochem Ireland
Estechpharma Co., Ltd.
Chongqing Shenghuaxi Pharm Co.,Ltd.
JINLAN Pharm-Drugs Technology Co., Ltd.
Ìý
Ìý
*If Applicable.
